144 related articles for article (PubMed ID: 29781558)
1. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.
Tofte N; Lindhardt M; Adamova K; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Kooy A; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Ruggenenti PL; Rutters F; Rychlík I; Spasovski G; Speeckaert M; Trillini M; von der Leyen H; Rossing P
Diabet Med; 2018 Oct; 35(10):1375-1382. PubMed ID: 29781558
[TBL] [Abstract][Full Text] [Related]
2. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
3. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.
Lindhardt M; Persson F; Currie G; Pontillo C; Beige J; Delles C; von der Leyen H; Mischak H; Navis G; Noutsou M; Ortiz A; Ruggenenti PL; Rychlik I; Spasovski G; Rossing P
BMJ Open; 2016 Mar; 6(3):e010310. PubMed ID: 26936907
[TBL] [Abstract][Full Text] [Related]
4. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Lindhardt M; Persson F; Zürbig P; Stalmach A; Mischak H; de Zeeuw D; Lambers Heerspink H; Klein R; Orchard T; Porta M; Fuller J; Bilous R; Chaturvedi N; Parving HH; Rossing P
Nephrol Dial Transplant; 2017 Nov; 32(11):1866-1873. PubMed ID: 27507891
[TBL] [Abstract][Full Text] [Related]
5. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.
Currie GE; von Scholten BJ; Mary S; Flores Guerrero JL; Lindhardt M; Reinhard H; Jacobsen PK; Mullen W; Parving HH; Mischak H; Rossing P; Delles C
Cardiovasc Diabetol; 2018 Apr; 17(1):50. PubMed ID: 29625564
[TBL] [Abstract][Full Text] [Related]
6. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
Siwy J; Schanstra JP; Argiles A; Bakker SJ; Beige J; Boucek P; Brand K; Delles C; Duranton F; Fernandez-Fernandez B; Jankowski ML; Al Khatib M; Kunt T; Lajer M; Lichtinghagen R; Lindhardt M; Maahs DM; Mischak H; Mullen W; Navis G; Noutsou M; Ortiz A; Persson F; Petrie JR; Roob JM; Rossing P; Ruggenenti P; Rychlik I; Serra AL; Snell-Bergeon J; Spasovski G; Stojceva-Taneva O; Trillini M; von der Leyen H; Winklhofer-Roob BM; Zürbig P; Jankowski J
Nephrol Dial Transplant; 2014 Aug; 29(8):1563-70. PubMed ID: 24589724
[TBL] [Abstract][Full Text] [Related]
7. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
[TBL] [Abstract][Full Text] [Related]
8. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
Oellgaard J; Gæde P; Persson F; Rossing P; Parving HH; Pedersen O
J Diabetes Complications; 2018 Dec; 32(12):1133-1140. PubMed ID: 30282584
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
Critselis E; Vlahou A; Stel VS; Morton RL
Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria: A Randomized Clinical Trial.
Curovic VR; Eickhoff MK; Rönkkö T; Frimodt-Møller M; Hansen TW; Mischak H; Rossing P; Ahluwalia TS; Persson F
Diabetes Care; 2022 Nov; 45(11):2662-2668. PubMed ID: 35998283
[TBL] [Abstract][Full Text] [Related]
11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
12. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
13. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
[TBL] [Abstract][Full Text] [Related]
14. [Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century].
Shestakova MV
Ter Arkh; 2016; 88(6):84-88. PubMed ID: 27489899
[TBL] [Abstract][Full Text] [Related]
15. Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes.
Troya MI; Bonet J; Salinas I; Torres F; Bonal J; Sanmartí A; Romero R
Med Clin (Barc); 2016 Jan; 146(2):55-60. PubMed ID: 26343155
[TBL] [Abstract][Full Text] [Related]
16. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
18. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
19. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
[TBL] [Abstract][Full Text] [Related]
20. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
